Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
FlowCardia is a medical device company marketing catheters that reopen obstructed arteries in the legs, which can avoid amputation. Its lead product, the CROSSER™, uses high-frequency vibration to penetrate hard arterial blockages.
After Gilde led a large institutional financing round of growth capital, the company built a marketing and sales organization, expanded its product portfolio and developed into a high-growth, revenue-generating business. FlowCardia was acquired by C. R. Bard, Inc. (NYSE: BCR) in 2010. It was located in Sunnyvale, California.
More Flowcardia news
FlowCardia, Inc. Initiates CENTRAL Study Enrollment
FlowCardia, Inc. expands treatment options for patients with chronic total occlusion
FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance
FlowCardia, Inc. Appoints Deborah DeFilippo CFO
Venture&Growth
MicroTransponder
MicroTransponder is a U.S.-based, growth-stage company commercializing the Vivistim Paired VNS System, an implantable neurostimulation therapy that improves outcomes for chronic ischemic stroke survivors with upper limb motor deficits. Vivistim Paired VNS System is an implantable neurostimulation therapy that helps

Venture&Growth
Axonics Modulation Technologies
US MedTech company focused on neuromodulation.

Venture&Growth
AM-Pharma
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI).
